Cargando…

Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival

BACKGROUND: In cancer research the selection and definitions of survival endpoints are important and yet they are not used consistently. The aim of this study was to compare different survival endpoints in patients with primary colorectal cancer (CRC) and to understand the effect of second primary o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birgisson, Helgi, Wallin, Ulrik, Holmberg, Lars, Glimelius, Bengt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3209454/ https://www.ncbi.nlm.nih.gov/pubmed/21989154 http://dx.doi.org/10.1186/1471-2407-11-438

Ejemplares similares

Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer
por: Ghanipour, Lana, et al.
Publicado: (2016)

Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer
por: Birgisson, Helgi, et al.
Publicado: (2015)

Signet Ring Cell Colorectal and Appendiceal Cancer: A Small Signet Ring Cell Component Is Also Associated with Poor Outcome
por: Enblad, Malin, et al.
Publicado: (2023)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice
por: Sundström, Magnus, et al.
Publicado: (2010)

Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer
por: Wallin, U, et al.
Publicado: (2011)

A novel event-free survival endpoint in locally advanced pancreatic cancer
por: Hammel, Pascal, et al.
Publicado: (2021)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

Gains of Chromosome 1p and 15q are Associated with Poor Survival After Cytoreductive Surgery and HIPEC for Treating Colorectal Peritoneal Metastases
por: Enblad, Malin, et al.
Publicado: (2019)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Plasma Protein Profiling Reveal Osteoprotegerin as a Marker of Prognostic Impact for Colorectal Cancer
por: Birgisson, Helgi, et al.
Publicado: (2018)

The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer.
por: Graf, W., et al.
Publicado: (1994)

Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity
por: Rasmussen, Markus, et al.
Publicado: (2011)

1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer
por: Mayrhofer, Markus, et al.
Publicado: (2014)

The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer.
por: Lindmark, G., et al.
Publicado: (1995)

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
por: Siesing, Christina, et al.
Publicado: (2017)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

Disease-free survival landmark analysis: a potential critical endpoint in triple-negative breast cancer
por: Zheng, Fangchao, et al.
Publicado: (2022)

Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer
por: Shimokawa, Mototsugu, et al.
Publicado: (2018)

Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients
por: Glimelius, Bengt, et al.
Publicado: (2020)

Serum inflammatory markers and colorectal cancer risk and survival
por: Ghuman, Sundeep, et al.
Publicado: (2017)

Clinical characteristics of second primary cancer in colorectal cancer patients: the impact of colorectal cancer or other second cancer occurring first
por: Sun, Li-Chu, et al.
Publicado: (2014)

Low‐dose aspirin use and colorectal cancer survival in 32,195 patients—A national cohort study
por: Shahrivar, Mehrnoosh, et al.
Publicado: (2022)

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
por: Forsythe, Anna, et al.
Publicado: (2018)

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Is England closing the international gap in cancer survival?
por: Walters, Sarah, et al.
Publicado: (2015)

Survival for endometrial cancer as a second primary malignancy
por: Medina, Heidy N., et al.
Publicado: (2022)

Survival after Locoregional Recurrence or Second Primary Breast Cancer: Impact of the Disease-Free Interval
por: Witteveen, Annemieke, et al.
Publicado: (2015)

Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2017)

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
por: Nie, Run-Cong, et al.
Publicado: (2020)

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2016)

Chromothripsis and progression-free survival in metastatic colorectal cancer
por: Skuja, Elina, et al.
Publicado: (2017)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer
por: Choi, Eunji, et al.
Publicado: (2021)

Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review
por: Zhu, Jie, et al.
Publicado: (2022)

Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical Costs
por: Inci, Kamuran, et al.
Publicado: (2023)

Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study
por: Mahteme, H, et al.
Publicado: (2004)

Second Primary Cancers in Melanoma Patients Critically Shorten Survival
por: Zheng, Guoqiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l20raip47chmeke1brdrrs1sh9